ResearcherJesse Brown VA Medical CenterActive in the last 2 years
John P O'Bryan
Matched on ORCID iD 0000-0001-5386-1080; OpenAlex author ID A5084266690; NIH RePORTER profile ID 1881786. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 1
- Labs led
- 0
- Collaborators
- 16
2022: 1 paper · 2023: 1 paper · 2024: 2 papers, 1 grant · 2025: 1 paper
Papers 5
- Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.3390/biom15050645↗
- HSP70-mediated mitochondrial dynamics and autophagy represent a novel vulnerability in pancreatic cancer. Co-author DOI 10.1038/s41418-024-01310-9↗
- A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17). Co-author DOI 10.3390/antib13040101↗
- Secreted frizzled related-protein 2 is prognostic for human pancreatic cancer patient survival and is associated with fibrosis. Co-author DOI 10.3233/cbm-220044↗
- Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis. Last author DOI 10.1080/21541248.2021.1906621↗
Grants 1
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- G. Aaron Hobbs · 3 shared papers, 2024–2025 · strength 0.60
- Paper Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in … DOI 10.3390/biom15050645↗
- Paper A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA… DOI 10.3390/antib13040101↗
- Paper HSP70-mediated mitochondrial dynamics and autophagy represent a novel vulnerability in pancreatic cancer. DOI 10.1038/s41418-024-01310-9↗
- Nathan G. Dolloff · 3 shared papers, 2023–2025 · strength 0.59
- Paper Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in … DOI 10.3390/biom15050645↗
- Paper A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA… DOI 10.3390/antib13040101↗
- Paper Secreted frizzled related-protein 2 is prognostic for human pancreatic cancer patient survival and is associated with f… DOI 10.3233/cbm-220044↗
- Reeder M. Robinson · 2 shared papers, 2024–2025 · strength 0.43
- Paper Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in … DOI 10.3390/biom15050645↗
- Paper A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA… DOI 10.3390/antib13040101↗
- Benjamin N. Christopher · 2 shared papers, 2024–2025 · strength 0.43
- Paper Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in … DOI 10.3390/biom15050645↗
- Paper A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA… DOI 10.3390/antib13040101↗
- Julie B. Siegel · 2 shared papers, 2023–2024 · strength 0.35
- Paper A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA… DOI 10.3390/antib13040101↗
- Paper Secreted frizzled related-protein 2 is prognostic for human pancreatic cancer patient survival and is associated with f… DOI 10.3233/cbm-220044↗
- Nancy Klauber‐DeMore · 2 shared papers, 2023–2024 · strength 0.35
- Paper A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA… DOI 10.3390/antib13040101↗
- Paper Secreted frizzled related-protein 2 is prognostic for human pancreatic cancer patient survival and is associated with f… DOI 10.3233/cbm-220044↗
- Denis C. Guttridge D · 1 shared paper, 2025 · strength 0.24
- Rachel A. Burge · 1 shared paper, 2024 · strength 0.20
- Thibaut Barnoud · 1 shared paper, 2024 · strength 0.17
- David F. Kashatus · 1 shared paper, 2024 · strength 0.17
- Salma Sharmin · 1 shared paper, 2024 · strength 0.17
- Giulia D. S. Ferretti · 1 shared paper, 2024 · strength 0.17
- Julia E. Lefler · 1 shared paper, 2022 · strength 0.14
- Catherine B. MarElia · 1 shared paper, 2022 · strength 0.14
- Imran Khan · 1 shared paper, 2022 · strength 0.14
- Michael C. Ostrowski · 1 shared paper, 2022 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.